We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Research into the regulation of exams, assessments and qualifications.
Sets out which policies DfT has committed to review in legislation and when those reviews will take place.
First published during the 2010 to 2015 Conservative and Liberal Democrat coalition government
Our approach to regulation and enforcement during the coronavirus outbreak.
The government's summary of a proposed delegated regulation which makes a series of changes to detailed specifications in the 'framework' regulation 2018/858.
First published during the 2019 to 2022 Johnson Conservative government
This series brings together all documents relating to DECC statement of new regulation (SONR).
The government seeks views on updating the Securitisation Regulation to ensure it best delivers for the UK’s financial sector and real economy.
The Office for Nuclear Regulation is the UK’s independent nuclear regulator. Its mission is to protect society by securing safe nuclear operations. ONR is a public corporation of the Department for Work and Pensions .
A Guide for Employers and Employees to the role of the Central Arbitration Committee (CAC) for these regulations
What you need to do to place a medical device on the Great Britain, Northern Ireland and European Union (EU) markets.
Information about the EU Regulations and their implementation in Northern Ireland
Following MHRA approval of a clinical trial, early breast cancer patients on endocrine-based therapy can benefit from a study with camizestrant.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).